Filing Details
- Accession Number:
- 0000899243-22-026840
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-07-27 16:17:44
- Reporting Period:
- 2022-07-25
- Accepted Time:
- 2022-07-27 16:17:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242825 | M Jeffrey Leiden | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-07-25 | 60,342 | $91.05 | 134,502 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-07-25 | 13,869 | $279.44 | 120,633 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 32,983 | $280.37 | 87,650 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 34,090 | $281.27 | 53,560 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 40,666 | $282.43 | 12,894 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-07-25 | 10,471 | $283.42 | 2,423 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2022-07-25 | 60,342 | $0.00 | 60,342 | $91.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 33,524 | 2026-02-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 440 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $279.44 (range $278.90 to $279.89).
- Open market sales reported on this line occurred at a weighted average price of $280.37 (range $279.90 to $280.88).
- Open market sales reported on this line occurred at a weighted average price of $281.27 (range $280.90 to $281.89).
- Open market sales reported on this line occurred at a weighted average price of $282.43 (range $281.90 to $282.89).
- Open market sales reported on this line occurred at a weighted average price of $283.42 (range $282.90 to $283.84).
- Fully vested.
Billionaire Hedge Funds
